[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655638":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":22,"studyPopulation":11,"armGroups":23,"interventions":44,"overallOfficials":11,"centralContacts":65,"locations":11,"responsibleParty":73,"collaborators":11,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":11,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":11,"enrollmentInfo":84,"targetDuration":11,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":11,"overallStatus":93,"whyStopped":11,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":11},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change in HbA1c(Hemoglobin a1c) from baseline at Week 24 after administration of IP(Investigator's Product)",null,"Baseline, Week 24",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"DOUBLE",[20,21],"PARTICIPANT","INVESTIGATOR","Condition or disease: Type 2 Diabetes Mellitus",[24,33,39],{"label":25,"type":26,"description":27,"interventionNames":28},"Test Group","EXPERIMENTAL","AD-233A+AD-233B+AD-233C and\u002For AD-233D",[29,30,31,32],"Drug: AD-233A","Drug: AD-233B","Drug: AD-233C","Drug: AD-233D",{"label":34,"type":35,"description":36,"interventionNames":37},"Control Group 1","ACTIVE_COMPARATOR","AD-233A Placebo+AD-233B+AD-233C and\u002For AD-233D",[30,31,32,38],"Drug: AD-233A Placebo",{"label":40,"type":35,"description":41,"interventionNames":42},"Control Group 2","AD-233A+AD-233B Placebo+AD-233C and\u002For AD-233D",[29,31,32,43],"Drug: AD-233B Placebo",[45,50,53,56,59,62],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":11},"DRUG","AD-233A","PO, Once daily(QD), 24 weeks",[40,25],{"type":46,"name":51,"description":48,"armGroupLabels":52,"otherNames":11},"AD-233B",[34,25],{"type":46,"name":54,"description":48,"armGroupLabels":55,"otherNames":11},"AD-233C",[34,40,25],{"type":46,"name":57,"description":48,"armGroupLabels":58,"otherNames":11},"AD-233D",[34,40,25],{"type":46,"name":60,"description":48,"armGroupLabels":61,"otherNames":11},"AD-233A Placebo",[34],{"type":46,"name":63,"description":48,"armGroupLabels":64,"otherNames":11},"AD-233B Placebo",[40],[66,71],{"name":67,"role":68,"phone":69,"phoneExt":11,"email":70},"Hanna Yang","CONTACT","82+01084267236","hnyang@addpharma.co.kr",{"name":72,"role":68,"phone":11,"phoneExt":11,"email":11},"Seong rae Kim, Principal Investigator",{"type":74,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100655638","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-ad-233a-ad-233b-ad-233c-andor-ad-233d-combination-therapy-100655638",false,"NCT07816198","A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and\u002For AD-233D Combination Therapy","A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and\u002For AD-233D Combination Therapy in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Signed informed consent\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Subjects with severe diabetic complications\n* Other exclusions applied","ALL","19 Years",{"count":85,"type":86},354,"ESTIMATED","INTERVENTIONAL",[89],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and\u002For AD-233D combination therapy",[92],"Type 2 Diabetes Mellitus (T2DM)","NOT_YET_RECRUITING","2026-09-14",{"date":96,"type":97},"2026-09-16","ACTUAL",{"date":99,"type":86},"2026-09-30",{"date":101,"type":86},"2028-06-30",{"name":5,"class":6}]